170 - Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 - Powles, T; Bellmunt, J; Castellano, D (Eur Urol, 2017)
et al.